Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, Univ-Lyon, 69500 Bron, France.
Laboratoire CarMeN-MERISM Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, Univ-Lyon, 69921 Oullins, France.
Int J Mol Sci. 2022 Mar 25;23(7):3569. doi: 10.3390/ijms23073569.
Diabetic cardiomyopathy (DCM) is a leading complication in type 2 diabetes patients. Recently, we have shown that the reticulum-mitochondria Ca uncoupling is an early and reversible trigger of the cardiac dysfunction in a diet-induced mouse model of DCM. Metformin is a first-line antidiabetic drug with recognized cardioprotective effect in myocardial infarction. Whether metformin could prevent the progression of DCM remains not well understood. We therefore investigated the effect of a chronic 6-week metformin treatment on the reticulum-mitochondria Ca coupling and the cardiac function in our high-fat high-sucrose diet (HFHSD) mouse model of DCM. Although metformin rescued the glycemic regulation in the HFHSD mice, it did not preserve the reticulum-mitochondria Ca coupling either structurally or functionally. Metformin also did not prevent the progression towards cardiac dysfunction, i.e., cardiac hypertrophy and strain dysfunction. In summary, despite its cardioprotective role, metformin is not sufficient to delay the progression to early DCM.
糖尿病心肌病(DCM)是 2 型糖尿病患者的主要并发症。最近,我们已经表明,内质网-线粒体 Ca2+解耦联是 DCM 饮食诱导小鼠模型中心脏功能障碍的早期和可逆转的触发因素。二甲双胍是一种一线抗糖尿病药物,对心肌梗死具有公认的心脏保护作用。二甲双胍是否能预防 DCM 的进展尚不清楚。因此,我们研究了慢性 6 周二甲双胍治疗对我们的高脂肪高蔗糖饮食(HFHSD)DCM 小鼠模型中线粒体 Ca2+偶联和心脏功能的影响。尽管二甲双胍挽救了 HFHSD 小鼠的血糖调节,但它既没有在结构上也没有在功能上保留内质网-线粒体 Ca2+偶联。二甲双胍也不能阻止向心脏功能障碍的进展,即心脏肥大和应变功能障碍。总之,尽管二甲双胍具有心脏保护作用,但它不足以延缓早期 DCM 的进展。